you are here: HomeNewsBiocon
biocon
Jump to
1508 Results Found
  • Biocon Q3 PAT seen up 106.5% YoY to Rs. 190 cr: Sharekhan Jan 18, 2019 02:58 PM IST

    Biocon Q3 PAT seen up 106.5% YoY to Rs. 190 cr: Sharekhan

    Net Sales are expected to increase by 32.4 percent Y-o-Y (up 6 percent Q-o-Q) to Rs. 1,400.7 crore, according to Sharekhan.

  • Biocon Q3 PAT seen up 105.4% YoY to Rs. 188.7 cr: ICICI Direct Jan 11, 2019 05:26 PM IST

    Biocon Q3 PAT seen up 105.4% YoY to Rs. 188.7 cr: ICICI Direct

    Net Sales are expected to increase by 30.7 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs. 1,382.4 crore, according to ICICI Direct.

  • European Commission okays Mylan, Biocon's biosimilar of cancer drug Dec 19, 2018 11:46 AM IST

    European Commission okays Mylan, Biocon's biosimilar of cancer drug

    Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer.

  • USFDA completes Biocon's Telangana plant inspection Dec 17, 2018 11:44 AM IST

    USFDA completes Biocon's Telangana plant inspection

    The inspection was concluded without any observations and no Form 483 was issued, the company added.

  • Biocon, Mylan joint product Fulphila gets approval in EU Nov 30, 2018 06:22 PM IST

    Biocon, Mylan joint product Fulphila gets approval in EU

    Fulphila, a biosimilar Pegfilgrastim, jointly developed by Biocon and Mylan, has been approved in European Union (EU), Biocon said in a regulatory filing.

  • Biocon chief bats for easing regulations on biotech sector Nov 29, 2018 04:45 PM IST

    Biocon chief bats for easing regulations on biotech sector

    "The erstwhile UPA regime and the present Modi government have taken some good steps, but have not done enough to improve the economy," Shaw told PTI in an interview after the inauguration of Bengaluru Tech Summit 2018.

  • Crucial resistance for Nifty at 10,740-10,750; USL among YES Securities' top bets Nov 28, 2018 10:34 AM IST

    Crucial resistance for Nifty at 10,740-10,750; USL among YES Securities' top bets

    A sustained move above the 200-SMA i.e. 10,753 will extend the uptrend taking the Index to levels of 10,850-10,980. However, failure to cross this resistance on the way up can trigger profit booking.

  • Biocon opens higher as Citi maintains buy rating Nov 09, 2018 09:41 AM IST

    Biocon opens higher as Citi maintains buy rating

    Citi added that Biocon is one of its top picks. Risk-reward ratio is favourable at current levels

  • Nifty target for Diwali 2019 at 11,500, like Biocon, Sun Pharma for long term: Edelweiss Nov 08, 2018 11:16 AM IST

    Nifty target for Diwali 2019 at 11,500, like Biocon, Sun Pharma for long term: Edelweiss

    Indian markets will be impacted by many impending global factors in the next 1 year. As global trade tiffs are increasingly turning into standoffs, trade and capital flows to and from India would definitely be affected.

  • Expect steady growth in biosimilars segment going forward, says Kiran Mazumdar Shaw of Biocon Oct 26, 2018 09:36 PM IST

    Expect steady growth in biosimilars segment going forward, says Kiran Mazumdar Shaw of Biocon

    “Overall, we have a nice basket of biosimilars for both the US and European market, which will set us up for a steady growth in that segment going forward,” said Shaw.

  • Diwali picks 2018: IIFL bets on 8 stocks to brighten up your portfolio Oct 26, 2018 02:46 PM IST

    Diwali picks 2018: IIFL bets on 8 stocks to brighten up your portfolio

    Brokerage house sees an upside of 19-34 percent in these stocks; names such as MindTree, RIL figure in the list.

  • Biocon Consolidated September 2018 Net Sales at Rs 1,321.00 crore, Up 36.38% Q-o-Q. Oct 26, 2018 12:32 PM IST

    Biocon Consolidated September 2018 Net Sales at Rs 1,321.00 crore, Up 36.38% Q-o-Q.

  • Biocon Standalone September 2018 Net Sales at Rs 708.90 crore, up 17.23% Q-o-Q Oct 26, 2018 12:31 PM IST

    Biocon Standalone September 2018 Net Sales at Rs 708.90 crore, up 17.23% Q-o-Q

  • Biocon Q2 net profit jumps 167% to Rs 184 crore, beats analyst estimates Oct 25, 2018 08:53 PM IST

    Biocon Q2 net profit jumps 167% to Rs 184 crore, beats analyst estimates

    The growth was led by the launch of biosimilar pegfilgrastim by Biocon's partner Mylan in US and strong performance across small molecules and research services segments.

  • Hunting for value? These 10 expert picks are a buy after recent fall Oct 23, 2018 10:31 AM IST

    Hunting for value? These 10 expert picks are a buy after recent fall

    Experts feel that investors sitting on cash should buy into markets in a scattered manner instead of making a lump sum payment.

  • Biocon inches closer for Europe approval of biosimilar Trastuzumab Oct 20, 2018 12:55 PM IST

    Biocon inches closer for Europe approval of biosimilar Trastuzumab

    Trastuzumab, the biosimilar version of Swiss drug maker Roche’s Herceptin had brand sales of $1.9 billion in Europe for the 12 months ended July 31, according to IQVIA.

  • FII View | Foreign investors cautious on India, pharma & consumption attractive: Steven Birch Oct 19, 2018 02:02 PM IST

    FII View | Foreign investors cautious on India, pharma & consumption attractive: Steven Birch

    According to the latest report by IMF, India is poised to grow at 7.4 percent in 2018 and 7.8 percent in 2019, making it the fastest growing economy among peers overtaking China.

  • Biocon Q2 PAT seen up 38.2% YoY to Rs. 123 cr: Sharekhan Oct 16, 2018 07:22 PM IST

    Biocon Q2 PAT seen up 38.2% YoY to Rs. 123 cr: Sharekhan

    Net Sales are expected to increase by 19.1 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 1,154 crore, according to Sharekhan.

  • Biocon Q2 PAT seen up 105.9% YoY to Rs. 141.6 cr: ICICI Direct Oct 12, 2018 04:07 PM IST

    Biocon Q2 PAT seen up 105.9% YoY to Rs. 141.6 cr: ICICI Direct

    Net Sales are expected to increase by 28.6 percent Y-o-Y (up 10.8 percent Q-o-Q) to Rs. 1,245.4 crore, according to ICICI Direct.

  • Biocon closer to Europe approval of biosimilar pegfilgrastim Sep 21, 2018 07:56 PM IST

    Biocon closer to Europe approval of biosimilar pegfilgrastim

    Amgen's Neulasta had brand sales of more than $450 million in Europe for the 12 months ending June 30, 2018, according to market research firm IQVIA.

  • Biocon Q1 net profit jumps 47% to Rs 120 crore, beats analyst estimates Jul 26, 2018 07:55 PM IST

    Biocon Q1 net profit jumps 47% to Rs 120 crore, beats analyst estimates

    Total revenue for the quarter under review grew 21 percent to Rs 1,192 crore in the April-June period.

  • Biocon Q1 preview: Net profit seen rising 44% on last year's low base Jul 26, 2018 10:22 AM IST

    Biocon Q1 preview: Net profit seen rising 44% on last year's low base

    The company's performance in the June quarter is also expected to augmented by the performance of its biologics, branded formulations and research services segments

  • Biocon Q1 PAT seen up 70.8% YoY to Rs. 138.9 cr: Kotak Jul 18, 2018 02:08 PM IST

    Biocon Q1 PAT seen up 70.8% YoY to Rs. 138.9 cr: Kotak

    Net Sales are expected to increase by 24.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 1,162 crore, according to Kotak.

  • History repeats: The most important assumption in Technical Analysis Jul 14, 2018 01:50 PM IST

    History repeats: The most important assumption in Technical Analysis

    When a set of factors that have panned out in the past tends to repeat itself in the future, we expect the same outcome to occur, as was observed in the past.

  • Biocon shares gain nearly 2% on EU GMP certification for Bengaluru facility Jul 05, 2018 10:21 AM IST

    Biocon shares gain nearly 2% on EU GMP certification for Bengaluru facility

    Bangalore facility is used for the manufacture of portfolio of biosimilars.

Sections